PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments

Phang, J. M., Pandhare, J., Zabirnyk, O., & Liu, Y. (2008). PPARγ and Proline Oxidase in Cancer. PPAR Research, 2008(), 785-793-073. https://doi.org/10.1155/2008/542694
Mackenzie, G. G., Rasheed, S., Wertheim, W., & Rigas, B. (2008). NO-Donating NSAIDs, PPARδ, and Cancer: Does PPARδ Contribute to Colon Carcinogenesis?. PPAR Research, 2008(), 231-241-122. https://doi.org/10.1155/2008/919572
郭盛助（1996）。Chemical Modification of Naturally Occurring Components and Development of New Anticancer Agent。中醫藥雜誌，7(1)，33-34。https://doi.org/10.6940/JCM.199604_7(1).09
Silswal, N., Parelkar, N. K., Wacker, M. J., Badr, M., & Andresen, J. (2012). PPARα-Independent Arterial Smooth Muscle Relaxant Effects of PPARα Agonists. PPAR Research, 2012(), 176-185. https://doi.org/10.1155/2012/302495
Yasui, Y., Kim, M., & Tanaka, T. (2008). PPAR Ligands for Cancer Chemoprevention. PPAR Research, 2008(), 815-824-077. https://doi.org/10.1155/2008/548919